MedPath

Fasudil

Generic Name
Fasudil
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C14H17N3O2S
CAS Number
103745-39-7
Unique Ingredient Identifier
Q0CH43PGXS
Background

Fasudil has been investigated in Carotid Stenosis.

Indication

用于改善蛛网膜下隙出血后的脑血管痉挛及伴发的脑缺血症状。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)

Phase 2
Recruiting
Conditions
Alzheimer Disease
Cognitive Decline, Mild
Interventions
Drug: Placebo
Drug: Fasudil
First Posted Date
2024-04-12
Last Posted Date
2024-10-22
Lead Sponsor
Helse Stavanger HF
Target Recruit Count
200
Registration Number
NCT06362707
Locations
🇳🇴

University Hospital of North Norway, Tromsø, Nordland, Norway

🇳🇴

Haugesund Hospital, Haugesund, Rogaland, Norway

🇳🇴

Stavanger University Hospital, Stavanger, Rogaland, Norway

and more 3 locations

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

Phase 2
Conditions
Progressive Supranuclear Palsy
Corticobasal Syndrome
Interventions
Drug: Fasudil
First Posted Date
2021-02-02
Last Posted Date
2022-06-03
Lead Sponsor
Woolsey Pharmaceuticals
Target Recruit Count
15
Registration Number
NCT04734379
Locations
🇺🇸

University of California Weill Institute for Neurosciences, San Francisco, California, United States

Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Fasudil
Drug: Placebo
First Posted Date
2019-01-03
Last Posted Date
2023-11-30
Lead Sponsor
University Medical Center Goettingen
Target Recruit Count
120
Registration Number
NCT03792490
Locations
🇫🇷

Centre Hospitalier Universitaire Tours, Tours, France

🇩🇪

University Medical Center Göttingen, Göttingen, Germany

🇩🇪

Klinikum rechts der Isar der Technischen Universität München, München, Germany

and more 12 locations

A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Fasudil
First Posted Date
2013-09-05
Last Posted Date
2013-09-06
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
10
Registration Number
NCT01935518
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

Phase 3
Completed
Conditions
Raynaud
Scleroderma
Interventions
Drug: Fasudil
First Posted Date
2007-07-10
Last Posted Date
2014-11-04
Lead Sponsor
Johns Hopkins University
Target Recruit Count
17
Registration Number
NCT00498615
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

The Effect of Fasudil on Vascular Function in Humans

Phase 2
Completed
Conditions
Atherosclerosis
Hypercholesterolemia
First Posted Date
2005-07-19
Last Posted Date
2008-09-30
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
60
Registration Number
NCT00120718
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy